On 7 June 2013, orphan designation (EU/3/13/1135) was granted by the European Commission to Dompé S.p.A., Italy, for recombinant human nerve growth factor for the treatment of retinitis pigmentosa.
The sponsorship was transferred to Dompé farmaceutici s.p.a., Italy, in March 2015.
For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.
Recombinant human nerve growth factor
|Disease / condition||
Treatment of retinitis pigmentosa
|Date of decision||
|Orphan decision number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.